Jeffrey A. Lieberman, M.D.

New York State Psychiatric Institute/Columbia University Medical Center, New York, NY, United States 
"Jeffrey Lieberman"
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Kantrowitz JT, Dong Z, Milak MS, et al. (2021) Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder. Translational Psychiatry. 11: 419
Paul SM, Breier A, Lieberman JA, et al. (2021) Clinical Trial of New Drug for Schizophrenia. Reply. The New England Journal of Medicine. 384: e105
Lieberman JA. (2021) Back to the Future - The Therapeutic Potential of Psychedelic Drugs. The New England Journal of Medicine. 384: 1460-1461
Girgis RR, Basavaraju R, France J, et al. (2021) An exploratory magnetic resonance imaging study of suicidal ideation in individuals at clinical high-risk for psychosis. Psychiatry Research. Neuroimaging. 312: 111287
Brannan SK, Sawchak S, Miller AC, et al. (2021) Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. The New England Journal of Medicine. 384: 717-726
Brucato G, Appelbaum PS, Hesson H, et al. (2021) Psychotic symptoms in mass shootings . mass murders not involving firearms: findings from the Columbia mass murder database. Psychological Medicine. 1-9
Girgis RR, Lieberman JA. (2020) Anti-viral properties of antipsychotic medications in the time of COVID-19. Psychiatry Research. 295: 113626
Lawrence RE, Appelbaum PS, Lieberman JA. (2020) A historical review of placebo-controlled, relapse prevention trials in schizophrenia: The loss of clinical equipoise. Schizophrenia Research
Girgis RR, Slifstein M, Brucato G, et al. (2020) Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [C]-(+)-PHNO PET with methylphenidate challenge study. Molecular Psychiatry
Lu JY, Tiwari AK, Freeman N, et al. (2020) Liver enzyme gene and tardive dyskinesia. Pharmacogenomics
See more...